EUVIMEDEUVIMED entdecken
Crossref

Targeting GPX4 to Overcome Sorafenib Resistance of Human Hepatocellular Carcinoma by Inducing Ferroptosis

Han-Hsuan Tang, Chi-Pei Hsu, Pin-Yu Su, Shu-Ping Tsai, Ly Hien Doan, Ching-Ying Chen, Hsin-Chih Chen, Pao-Yuan Wang, Tai-Shan Cheng, Chi-Ying F Huang iD, Chun-Li Su iD

Journal of Cellular Physiology · 2025-08 · 240 (8)

DOI: 10.1002/jcp.70078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Physiology, online erschienen am 05.08.2025. Verfasst von Han-Hsuan Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program of Nutrition Science, School of Life Science, National Taiwan Normal University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Ferroptosis, Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. Sorafenib, a multikinase inhibitor, has been approved as a first‐line systemic therapeutic for HCC patients based on the results of two large clinical trials, in which sorafenib significantly increased life expectancy of patients with Child Pugh A advanced stage of liver cancer, no matter which races they were or whether being infected with hepatitis B or C virus; however, its efficacy is compromised by the resistance of the tumor cells. By using integrative bioinformatics analysis, we identified ferroptosis as a candidate to modulate sorafenib‐resistant HCC. Ferroptosis is a novel, iron‐dependent, non‐apoptotic regulated cell death with characteristics of impaired lipid peroxide repair, redox active iron, and the oxidation of polyunsaturated fatty acids. Here, glutathione peroxidase 4 (GPX4) was further identified as a favorable prognostic factor in cancer survival by analyzing data repositories. Compared to the parental human HCC Huh7 cells, lower expression of GPX4, dysregulated iron homeostasis, and higher expression of acyl‐CoA synthetase long‐chain family member 4 were observed in sorafenib‐resistant Huh7R cells, and the Huh7R cells exhibited higher sensitivity to ferroptosis induction exerted by RSL3, a GPX4 inhibitor. The RSL3‐induced ferroptosis was attenuated by lysosomal blocker bafilomycin A1, indicating that lysosomal degradation of ferritin may confer sensitivity to GPX4‐inactivation‐induced ferroptosis by providing accessible iron. Taken together, our findings demonstrate that GPX4‐inactivation‐induced ferroptosis is a promising and effective treatment option capable of overcoming sorafenib resistance in liver cancer, and our novel gene expression‐screening platform via integrated analysis of differentially expressed genes and pathways allows efficient identification of therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisSorafenibCarcinoma, HepatocellularLiver NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseDrug Resistance, NeoplasmHumansCell Line, TumorIronGene Expression Regulation, NeoplasticAntineoplastic AgentsCarbolines

Stichwörter der Autor:innen

GPX4autophagyferroptosishepatocellular carcinomairon

Substanzen

SorafenibPhospholipid Hydroperoxide Glutathione PeroxidaseIronAntineoplastic AgentsRSL3 compoundCarbolines

Autor:innen und Institutionen

  • Graduate Program of Nutrition Science, School of Life Science, National Taiwan Normal University, Taipei, Taiwan.
  • Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Instrument Center, National Defense Medical Center, Taipei, Taiwan.
  • Department of Dietetics, National Taiwan University Hospital, Taipei, Taiwan.
  • Taiwan International Graduate Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan.
  • Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

ORCID-Profile: Chi-Ying F Huang, Chun-Li Su

Zitieren

APA

Tang, H. H., Hsu, C. P., Su, P. Y., Tsai, S. P., Doan, L. H., Chen, C. Y., Chen, H. C., Wang, P. Y., Cheng, T. S., Huang, C. F., & Su, C. L. (2025). Targeting GPX4 to Overcome Sorafenib Resistance of Human Hepatocellular Carcinoma by Inducing Ferroptosis. Journal of Cellular Physiology, 240(8). https://doi.org/10.1002/jcp.70078

Vancouver

Tang HH, Hsu CP, Su PY, Tsai SP, Doan LH, Chen CY, et al. Targeting GPX4 to Overcome Sorafenib Resistance of Human Hepatocellular Carcinoma by Inducing Ferroptosis. Journal of Cellular Physiology. 2025;240(8). doi:10.1002/jcp.70078

BibTeX
@article{Tang2025,
  author = {Tang, Han-Hsuan and Hsu, Chi-Pei and Su, Pin-Yu and Tsai, Shu-Ping and Doan, Ly Hien and Chen, Ching-Ying and Chen, Hsin-Chih and Wang, Pao-Yuan and Cheng, Tai-Shan and Huang, Chi-Ying F and Su, Chun-Li},
  title = {Targeting GPX4 to Overcome Sorafenib Resistance of Human Hepatocellular Carcinoma by Inducing Ferroptosis},
  journal = {Journal of Cellular Physiology},
  year = {2025},
  volume = {240},
  number = {8},
  doi = {10.1002/jcp.70078}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche